| abstract |
The present invention relates to delayed onset, extended release, isosorbide mononitrate (ISMN) formulations, and with methods for use in the treatment, prevention, reduction, inversion and / or management of nitrate tolerance and / or cardiovascular conditions. In particular, the present invention relates to a formulation of delayed onset of daily administration, extended release, which (1) provides a subject with an effective amount for the therapeutic use of ISMN during the first hours of the morning before and after of waking up, (2) continues to provide an effective amount for the therapeutic use of ISMN during the waking hours of the day, and (3) provides a reduction, or a decrease, of plasma ISMN levels to treat, prevent, reduce , reverse and / or manage nitrate tolerance. |